Introduction
============

Multimodal therapy for patients with unresectable primary and recurrent malignant tumors prolongs survival times. However, malignant large bowel obstruction (MLBO) and fistula formation, such as rectovaginal fistula caused by malignant tumor invasion, impair quality of life (QOL).

Colonic metallic stent (CMS) placement is indicated for MLBO palliation because of its high success rate and low complication rate^[@B1]-[@B6])^. However, CMS cannot be performed in patients with a high risk of clinical failure, including those with severe adhesions after laparotomy, bowel obstruction at multiple sites, and severe symptoms related to fistula formation and aggressive tumor invasion. In these patients, palliative interventions include stoma creation and bypass surgery.

Palliative ileostomies and colostomies are usually created at the sigmoid or transverse colon, but it is not clear that either type of ostomy is superior in terms of QOL.

The aim of this study was to compare short-term outcomes between palliative ileostomy and colostomy in patients with MLBO.

Method
======

MLBO was defined as complete bowel obstruction, caused by a malignant tumor, that was diagnosed by computed tomography and required decompression.

This was a retrospective study of patients with MLBO who required stoma creation between January 2005 and December 2016 at Toho University Omori Medical Center.

We identified 82 patients with MLBO caused by unresectable primary or recurrent malignant tumor and evaluated the following factors: sex; age; cause of MLBO; presence of preoperative stoma site marking; surgical outcomes (operative time, blood loss, mortality, surgical and stoma-related complications, and hospital stay); and QOL (relief of obstructive symptoms, resumption of oral intake, period to oral intake, and clinical success). Surgical and stoma-related complications were scored according to the Clavien-Dindo (C-D) classification^[@B7])^. Clinical success was defined as the ability to pass flatus and stool after oral intake and relief of obstructive symptoms.

The study was approved by the ethics committee of Toho University Omori Medical Center (No. M18016). Also, informed consent was obtained from all study patients.

Statistical Analysis
====================

The ileostomy group was compared with the colostomy group using the Chi square and Mann-Whitney U tests for categorical and continuous data, respectively. Continuous values were presented as medians (range). Statistical significance was considered as p \< 0.05. All data analysis was performed using SPP statistics for Windows, version 22.0 (IBM SPSS, New York, USA).

Results
=======

Patient characteristics
-----------------------

Patient characteristics are shown in [Table 1](#t001){ref-type="table"}. The study group consisted of 40 men and 42 women with a median age of 68.5 years (range, 26 years - 91 years). Malignant diseases leading to MLBO included colorectal cancer in 44 (53.6%) patients, gastric cancer in 19 (23.2%) patients, pancreatic and biliary ductal cancer in 6 (7.3%) patients, urological cancer in 3 (3.7%) patients, gynecological malignancies in 8 (9.8%) patients, and other cancers in 2 (2.4%) patients. Preoperative physical status included 5 (6.1%) patients at American Society of Anaesthesiologists physical status (ASA-PS) classification grade I, 64 (78.0%) at grade II, and 13 (15.9%) at grade III. Preoperative stoma site marking was performed by nurses and/or surgeons in 72 (87.8%) patients. There were no significant differences for the patients\' characteristics between the two groups.

###### 

Ileostomy and Colostomy Patient Characteristics.

                                  Total          Ileostomy group   Colostomy group   p value
  ------------------------------- -------------- ----------------- ----------------- ---------
  N                               82             33                49                
  Age\* (range)                   68.5 (26-91)   69 (26-88)        68 (47-91)        0.504
  Gender                                                                             0.965
  Male                            40 (48.8)      16 (48.5)         24 (49.0)         
  Female                          42 (51.2)      17 (51.5)         25 (51.0)         
  Primary disease                                                                    0.142
  Colorectal                      44 (53.6)      16 (48.5)         28 (57.2)         
  Gastric                         19 (23.2)      13 (39.4)         6 (12.2)          
  Pancreatic and biliary ductal   6 (7.3)        3 (9.1)           3 (6.1)           
  Urological                      3 (3.7)        0                 3 (6.1)           
  Gynecological                   8 (9.8)        1 (3.0)           7 (14.3)          
  Others                          2 (2.4)        0                 2 (4.1)           
  ASA PS status, grade                                                               0.434
  I                               5 (6.1)        2 (6.1)           3 (6.1)           
  II                              64 (78.0)      24 (72.7)         40 (81.6)         
  III                             13 (15.9)      7 (21.2)          6 (12.2)          
  IV                              0              0                 0                 
  Stoma site marking                                                                 0.309
  Positive                        72 (87.8)      27 (81.8)         45 (91.8)         
  Negative                        10 (12.2)      6 (18.2)          4 (8.2)           

( ): %, \*: median, ASA PS = The American Society of Anesthesiologists physical status classification

Comparison of short-term outcomes between the ileostomy and colostomy groups
----------------------------------------------------------------------------

### Surgical outcomes

Surgical outcomes are shown in [Table 2](#t002){ref-type="table"}. The median operative time was significantly shorter in the ileostomy group than the colostomy group (113 minutes versus 129 minutes, p = 0.045). Median blood loss was significantly lower in the ileostomy group than the colostomy group (8 g versus 40 g, p = 0.037). Thirty-day mortality included 3 (9.1%) patients in the ileostomy group. Surgical complications occurred in 29 (35.4%) patients. There was no significant difference in the incidence of surgical complications between groups (p = 0.431). Major surgical complications, defined as grade III or IV according to the C-D classification system, occurred in 6 (18.2%) patients in the ileostomy group and 4 (8.2%) patients in the colostomy group. This difference was not statistically significant (p = 0.092). All patients resumed oral intake, and obstructive symptoms completely resolved. The median period to oral intake in the ileostomy group and the colostomy group were 3 days (range, 1 day-61 days) and 4 days (1 day-16 days), respectively. No statistically significant differences were observed between the two groups (p = 0.335). The median duration of hospital stay was similar in both groups (p = 0.509).

###### 

Comparison of Surgical Outcomes between Ileostomy and Colostomy.

                                                               Ileostomy group (n = 33)   Colostomy group (n = 49)   p value
  ------------------------------------------------------------ -------------------------- -------------------------- ---------
  Operative time, minutes\* (range)                            113 (38-463)               129 (16-427)               0.045
  Blood loss, g\* (range)                                      8 (0-1350)                 40 (0-1810)                0.037
  Mortality (%)                                                3 (9.1)                    0                          \-
  Surgical complications                                                                                             
  Negative                                                     23 (69.7)                  30 (61.2)                  0.431
  Positive (%)                                                 10 (30.3)                  19 (38.8)                  
  Grade I and II (%)                                           4 (12.2)                   15 (30.6)                  0.092
  Grade III and IV (%)                                         6 (18.2)                   4 (8.2)                    
  Oral intake resumption (%)                                   33 (100)                   49 (100)                   \-
  Obstructive symptoms improvement (%)                         33 (100)                   49 (100)                   \-
  Period to oral intake, day\* (range)                         3 (1-61)                   4 (1-16)                   0.335
  Hospital stay duration after stoma creation, day\* (range)   32 (10-151)                27 (10-111)                0.509

\*: median

### Stoma-related complications

Stoma-related complications occurred in 27 (32.9%) patients. They occurred significantly more frequently in the ileostomy group than the colostomy group \[16 patients (48.5%) vs. 11 patients (22.4%), p = 0.014\]. High output stoma \[6 patients (18.2%)\] and irritation \[5 patients (15.2%)\] occurred more frequently in the ileostomy group, while stoma dehiscence \[5 patients, (10.2%)\] occurred more frequently in the colostomy group ([Table 3](#t003){ref-type="table"}).

###### 

Comparison of Stoma-Related Complications between Ileostomy and Colostomy.

                Ileostomy group (n = 33)   Colostomy group (n = 49)                                         
  ------------- -------------------------- -------------------------- --- --- ------------- --- --- --- --- -------------
  Irritation    3                          2                          0   0   5 (15.2)      1   2   0   0   3 (6.1)
  Dehiscence    2                          0                          0   0   2 (6.1)       4   1   0   0   5 (10.2)
  High output   1                          5                          0   0   6 (18.2)      0   2   0   0   2 (4.1)
  Necrosis      0                          1                          0   0   1 (3.0)       0   1   0   0   1 (2.0)
  Prolapse      0                          0                          1   0   1 (3.0)       0   0   0   0   0 (0)
  Fistula       0                          1                          0   0   1 (3.0)       0   0   0   0   0 (0)
  Total         6                          9                          1   0   16\* (48.5)   5   6   0   0   11\* (22.4)

\*: p = 0.014, C-D classification = the Clavien-Dindo classification

Prognosis
=========

The median overall survival period of the ileostomy and colostomy groups were 86.5 days (range, 15 days -1515 days) and 157 days (range, 20 days -1597 days), respectively. After a median follow-up of 1345 days (range, 15 days -1597 days), overall survival rates were 9.1% in the ileostomy group and 0% in the colostomy group. There was no significant difference in overall survival between the two groups (p = 0.733, [Figure 1](#g001){ref-type="fig"}).

![Overall survival rates in the ileostomy group and in the colostomy group. After a median follow-up of 1345 days (range, 15 days-1597 days), overall survival rates were 9.1% in the ileostomy group and 0% in the colostomy group. There was no significant difference in overall survival between the two groups (p = 0.733).](2432-3853-3-0073-g001){#g001}

Discussion
==========

Bowel obstruction is a serious complication of several advanced malignant tumors, particularly pancreatic, gastric, and colorectal tumors, and peritoneal carcinomatosis of ovarian cancer. Bowel obstruction can significantly impair patient QOL. CMS is recommended as a therapeutic alternative to surgery, not only as a bridge to surgery but also for palliation. CMS leads to shorter duration of hospital stay, shorter time to initiation of chemotherapy, and lower rates of stoma formation compared with surgery. Conversely, palliative CMS is associated with a risk of short- and long-term complications such as perforation (0%-8.9%), stent migration (4.4%-8%), restenosis (4.4%-8%), and bleeding (0%-3.7%)^[@B1],[@B2],[@B5],[@B8]-[@B10])^. Furthermore, clinical failure of CMS insertion is significantly associated with a higher 30-day mortality^[@B11])^.

For patients such as those with severe adhesions after laparotomy or aggressive tumor invasion into the abdominal cavity, CMS insertion is technically difficult. Palliative surgery might be safer and improve obstructive symptoms more reliably than CMS placement. Generally, when permanent stoma creation is required, colostomy is recommended because of benefits in stoma management and patient self-care compared with ileostomy. In this study, all 82 patients had a life expectancy of more than two months and good-to-moderate ASA-PS. Preoperative CT revealed obstruction at multiple sites or ascites^[@B12])^. In this study, the operator chose either ileostomy or colostomy based on the situation at the time. All 82 patients achieved clinical success and had symptom improvement with stoma creation. The overall surgical complication rate of 35.4% is comparable to that reported by Scheidbach et al^[@B13])^, but the 30-day mortality included three patients in the ileostomy group. The three patients were in the terminal stage: one of them had cancer ascites due to recurrence of pancreatic cancer and the others had multiple liver metastases due to recurrence of colon cancer. For these patients with ascites and/or multiple liver metastases, palliative surgery CMS placement should have been performed^[@B12])^.

A randomized clinical trial by Law et al.^[@B14])^ showed that loop transverse colostomy for fecal diversion following low anterior resection with total mesorectal excision for rectal cancer caused few complications. Of four recent meta-analyses^[@B15]-[@B18])^, two recommended loop ileostomy for fecal diverting stoma after colorectal or coloanal anastomosis, and the other two found no differences between the two procedures. The authors concluded that high quality, large scale, randomized control studies were needed to obtain better evidence for making the decision between loop ileostomy or loop colostomy.

In this study, we compared short-term outcomes between ileostomy and colostomy to determine the superiority of one ostomy type for MLBO palliation. The ileostomy group had a significantly shorter operative time and significantly less blood loss than the colostomy group. The number of surgical complications was similar between the two groups. There was no significant difference in overall survival between the two groups. On the other hand, stoma-related complications, particularly major complications of C-D grade II or more, occurred more often in the ileostomy group than in the colostomy group. High output stoma was the most frequent major stoma-related complication in the ileostomy group. Stoma-related complications did not influence the duration of hospital stay. Patients with bowel obstruction tend to be dehydrated due to the accumulated of water and electrolytes in the intestine and poor fluid intake due to obstructive symptoms such as nausea and vomiting. While colonic stomas have the advantage of lower-volume, solid stools, and easier care after surgery, ileal stomas generally cause irritation, high output, and liquid stools^[@B17])^. This study suggests that palliative colostomy is superior to ileostomy due to the latter\'s more frequent stoma-related complications related to high output.

However, this study has several limitations, includig its small sample size and single-center retrospective design. Additional randomized controlled trials are needed to clarify the superiority of either ileostomy or colostomy for palliation in terms of safety and QOL.

The decision to perform palliative surgery can be challenging because of the delicate balance between the pros and cons of intervention. The decision is influenced by the level of obstruction, clinical stage of the cancer, overall prognosis, presence of ascites, and patient performance status. When ileostomy is the only option, aggressive interventions for high output stomas should be implemented.
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